Skip to main content
Getting Orkambi on the NHS is a bittersweet victory, but the fight goes on

AFTER a long and fraught four years, an agreement between Pharma company Vertex and the NHS has finally resulted in Orkambi and Symkevi, the “game-changing” cystic fibrosis drugs, being made available on the NHS. 

Vertex were originally asking £100,000 per patient, per year for Orkambi, which the NHS couldn’t afford, resulting in a protracted price negotiation that above anything else illustrates a system which requires fundamental change.

This conflict between private companies and their need to give returns to their shareholders operating in the medical arena where much more is at stake was highlighted by Just Treatment patient leader Emily Birchall who said: “This is absolutely brilliant news for patients and for all the families who have fought so hard to access Orkambi and other medicines for cystic fibrosis over the last four years.

Take out shares in the People's Press
Support the Morning Star
You have reached the free limit.
Subscribe to continue reading.
More from this author
A woman showing signs of depression (picture posed by a mode
Features / 14 October 2024
14 October 2024
PROFESSOR LINDA GASK spoke to Ruth Hunt from her home in Orkney about her new book, Out of Her Mind: How We Are Failing Women’s Mental Health and What Must Change
The burned down home of a working miner “scab” at Bolton
Fiction / 10 August 2023
10 August 2023
RUTH F HUNT recommends a collection of short stories that transform poverty into something that’s often tender and profound
Users mutual support
Opinion / 8 March 2022
8 March 2022
Could the overstretched system for mental health service users be supplemented by day centres? RUTH HUNT considers the options
Police at the scene outside an address in Meadow Close in th
Features / 28 May 2021
28 May 2021
As concerns are being expressed about police involvement in drawing up and delivering mental health crisis plans, RUTH HUNT looks at the troubling facts
Similar stories
'Skinny jab' manufacturer Lilly has a track record of lawsui
Features / 27 October 2024
27 October 2024
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
An electron micrograph of HIV-1 virus particles (colourized
Features / 13 September 2024
13 September 2024
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An elderly woman's hands
Britain / 22 August 2024
22 August 2024